Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Eisai GmbH, Edmund-Rumpler-Straße 3,60549 Frankfurt am Main, Germany, E-mail: medinfo_de@eisai.net
LENVIMA 4 mg hard capsules.
LENVIMA 10 mg hard capsules.
| Pharmaceutical Form |
|---|
|
Hard capsule. LENVIMA 4 mg hard capsules: A yellowish-red body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 4 mg” on the body. LENVIMA 10 mg hard capsules: A yellow body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 10 mg” on the body. |
LENVIMA 4 mg hard capsules: Each hard capsule contains 4 mg of lenvatinib (as mesylate).
LENVIMA 10 mg hard capsules: Each hard capsule contains 10 mg of lenvatinib (as mesylate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lenvatinib |
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET. |
| List of Excipients |
|---|
|
Capsule contents: Calcium carbonate Capsule shell: Hypromellose Printing ink: Shellac |
Polyamide/Aluminium/PVC/Aluminium blisters containing 10 capsules. Each carton contains 30, 60, or 90 hard capsules.
Not all pack sizes may be marketed.
Eisai GmbH, Edmund-Rumpler-Straße 3,60549 Frankfurt am Main, Germany, E-mail: medinfo_de@eisai.net
Lenvima 4 mg hard capsules:
EU/1/15/1002/001
EU/1/15/1002/003
EU/1/15/1002/004
Lenvima 10 mg hard capsules:
EU/1/15/1002/002
EU/1/15/1002/005
EU/1/15/1002/006
Date of first authorisation: 28 May 2015
Date of latest renewal: 20 May 2020
| Drug | Countries | |
|---|---|---|
| LENVIMA | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
